

Veronika J Wirtz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2808548/publications.pdf>

Version: 2024-02-01

112
papers

2,905
citations

236925

25
h-index

197818

49
g-index

122
all docs

122
docs citations

122
times ranked

4233
citing authors

#	ARTICLE	IF	CITATIONS
1	Hospitalisation and mortality from COVID-19 in Mexican indigenous people: a cross-sectional observational study. <i>Journal of Epidemiology and Community Health</i> , 2022, 76, 16-23.	3.7	11
2	OUP accepted manuscript. <i>International Journal of Pharmacy Practice</i> , 2022, , .	0.6	0
3	The Social Costs of Success: The Impact of World Trade Organization Rules on Insulin Prices in Bangladesh upon Graduation from Least Developed Country Status. <i>Asian Development Review</i> , 2022, 39, 239-279.	1.5	1
4	Household access to non-communicable disease medicines during universal health care roll-out in Kenya: A time series analysis. <i>PLoS ONE</i> , 2022, 17, e0266715.	2.5	4
5	Policy Space for Building Production Capabilities in the Pharmaceuticals Sector in Low- and Middle-Income Countries: Evidence from Bangladesh. <i>Journal of Globalization and Development</i> , 2022, 12, 221-261.	0.3	1
6	Commercial and Social Value of Pharmaceutical Industry-led Access Programs: Conceptual Framework and Descriptive Analysis. <i>Health Systems and Reform</i> , 2022, 8, e2057831.	1.2	1
7	Challenges of Guaranteeing Access to Medicines in Mexico: Lessons from Recent Changes in Pharmaceuticals Procurement. <i>Health Systems and Reform</i> , 2022, 8, .	1.2	3
8	Consumption of systemic antibiotics in India in 2019. , 2022, 4, 100025.		15
9	Incremental Risk of Developing Severe COVID-19 Among Mexican Patients With Diabetes Attributed to Social and Health Care Access Disadvantages. <i>Diabetes Care</i> , 2021, 44, 373-380.	8.6	23
10	Geographical accessibility of medicines: a systematic literature review of pharmacy mapping. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 28.	2.4	21
11	Phone-based monitoring to evaluate health policy and program implementation in Kenya. <i>Health Policy and Planning</i> , 2021, 36, 444-453.	2.7	3
12	Coping with access barriers to non-communicable disease medicines: qualitative patient interviews in eight counties in Kenya. <i>BMC Health Services Research</i> , 2021, 21, 417.	2.2	4
13	The implementation of pharmaceutical services in public hospitals in Mexico: an analysis of the legal framework and organizational practice. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 41.	2.4	5
14	Regional and state-level patterns of type 2 diabetes prevalence in Mexico over the last three decades. <i>Diabetes Research and Clinical Practice</i> , 2021, 177, 108927.	2.8	8
15	Diabetes mellitus as a risk factor for SARS-CoV-2 test positivity in Mexico: A propensity score matched study. <i>Diabetes Research and Clinical Practice</i> , 2021, 178, 108953.	2.8	1
16	Cross-sectional survey to describe medicine use among Syrian asylum seekers and refugees in a German federal state: looking beyond infectious diseases. <i>BMJ Open</i> , 2021, 11, e053044.	1.9	2
17	Public health insurance and ethnic disparities in maternal health care: the case of vulnerable Mexican women over the last 25 years. <i>Health Policy and Planning</i> , 2021, 36, 1671-1680.	2.7	6
18	Barriers to Accessing Medicines among Syrian Asylum Seekers and Refugees in a German Federal State. <i>International Journal of Environmental Research and Public Health</i> , 2021, 18, 519.	2.6	10

#	ARTICLE	IF	CITATIONS
19	Addressing the medicines access challenge through balance, evidence, collaboration and transparency: key take-away lessons of the 4th PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2021, 14, 18.	2.4	5
20	Probability and amount of medicines expenditure according to health insurance status in Kenya: A household survey in eight counties. <i>International Journal of Health Planning and Management</i> , 2021, , .	1.7	5
21	Outpatient cardiovascular diseases and diabetes medicines dispensing in the population with government health insurance in Syria between 2018 and 2019: a retrospective analysis. <i>BMC Health Services Research</i> , 2021, 21, 1088.	2.2	3
22	Access to Medicines for Non-Communicable Diseases (NCDS) during COVID-19 in Kenya: A Descriptive Commentary. <i>Health Systems and Reform</i> , 2021, 7, e1984865.	1.2	5
23	Veterinary antimicrobial resistance containment in Bangladesh: Evaluating the national action plan and scoping the evidence on implementation. <i>Journal of Global Antimicrobial Resistance</i> , 2020, 21, 105-115.	2.2	33
24	Outpatient Antibiotic Dispensing for the Population with Government Health Insurance in Syria in 2018â€“2019. <i>Antibiotics</i> , 2020, 9, 570.	3.7	9
25	Availability and prices of medicines for non-communicable diseases at health facilities and retail drug outlets in Kenya: a cross-sectional survey in eight counties. <i>BMJ Open</i> , 2020, 10, e035132.	1.9	21
26	Predictors of health facility readiness for diabetes service delivery in low- and middle-income countries: The case of Bangladesh. <i>Diabetes Research and Clinical Practice</i> , 2020, 169, 108417.	2.8	6
27	Bacterial antibiotic resistance development and mutagenesis following exposure to subinhibitory concentrations of fluoroquinolones in vitro: a systematic review of the literature. <i>JAC-Antimicrobial Resistance</i> , 2020, 2, dlaa068.	2.1	6
28	Registration timelines of antiretroviral medicines in Ghana and Kenya. <i>Aids</i> , 2020, 34, 1093-1095.	2.2	0
29	Benchmarking national action plans on antimicrobial resistance in eight selected LMICs: Focus on the veterinary sector strategies. <i>Journal of Global Health</i> , 2020, 10, 020414.	2.7	2
30	The Effects of Trade Agreements on Imports of Biologics: Evidence from Chile. <i>Journal of Globalization and Development</i> , 2020, 10, .	0.3	3
31	Public reporting on pharmaceutical industry-led access programs: alignment with the WHO medicine programs evaluation checklist. <i>Journal of Pharmaceutical Policy and Practice</i> , 2020, 13, 5.	2.4	1
32	COVID-19 and risks to the supply and quality of tests, drugs, and vaccines. <i>The Lancet Global Health</i> , 2020, 8, e754-e755.	6.3	128
33	Mission Hospital Responses to Challenges and Implications for their Future Role in Indiaâ€™s Health System. <i>Christian Journal for Global Health</i> , 2020, 7, 19-36.	0.1	2
34	Promoting Access to Cancer Medicines in Mexico: Seguro Popular Key Policy Components. , 2020, , 177-222.		1
35	The implementation of the bioequivalence certification policy in Chile: An analysis of market authorization data. <i>PLoS ONE</i> , 2019, 14, e0217334.	2.5	2
36	A perspective on global access to insulin: a descriptive study of the market, trade flows and prices. <i>Diabetic Medicine</i> , 2019, 36, 726-733.	2.3	20

#	ARTICLE	IF	CITATIONS
37	The costs of diabetes treatment in low- and middle-income countries: a systematic review. <i>BMJ Global Health</i> , 2019, 4, e001258.	4.7	88
38	Effect of Novartis Access on availability and price of non-communicable disease medicines in Kenya: a cluster-randomised controlled trial. <i>The Lancet Global Health</i> , 2019, 7, e492-e502.	6.3	38
39	Bacterial antibiotic resistance development and mutagenesis following exposure to subminimal inhibitory concentrations of fluoroquinolones in vitro: a systematic literature review protocol. <i>BMJ Open</i> , 2019, 9, e030747.	1.9	9
40	Evaluation of the effects of a generic substitution policy implemented in Chile. <i>BMJ Global Health</i> , 2019, 2, e000922.	4.7	6
41	The need for comprehensive and multidisciplinary training in substandard and falsified medicines for pharmacists. <i>BMJ Global Health</i> , 2019, 4, e001681.	4.7	11
42	Evaluation of pharmaceutical industry-led access programmes: a standardised framework. <i>BMJ Global Health</i> , 2019, 4, e001659.	4.7	2
43	Global access to quality-assured medical products: the Oxford Statement and call to action. <i>The Lancet Global Health</i> , 2019, 7, e1609-e1611.	6.3	32
44	Impacts of intellectual property provisions in trade treaties on access to medicine in low and middle income countries: a systematic review. <i>Globalization and Health</i> , 2019, 15, 88.	4.9	14
45	Essential medicines for universal health coverage. <i>Kazan Medical Journal</i> , 2019, 100, 4-111.	0.2	3
46	The prevalence and correlates of severe depression in a cohort of Mexican teachers. <i>Journal of Affective Disorders</i> , 2018, 234, 109-116.	4.1	19
47	Commitment to Impact: Strengthening Measurement of Industry-Led Access-to-Medicines Programs. <i>Health Systems and Reform</i> , 2018, 4, 188-193.	1.2	6
48	Access to asthma medicines at the household level in eight counties of Kenya. <i>International Journal of Tuberculosis and Lung Disease</i> , 2018, 22, 585-590.	1.2	10
49	A global accountability mechanism for access to essential medicines. <i>Lancet, The</i> , 2018, 392, 2418-2420.	13.7	9
50	Access to Antihypertensive Medicines at the Household Level. , 2018, 13, 247-253.e5.		5
51	Perceptions of Kenyan adults on access to medicines for non-communicable diseases: A qualitative study. <i>PLoS ONE</i> , 2018, 13, e0201917.	2.5	20
52	Equity in access to non-communicable disease medicines: a cross-sectional study in Kenya. <i>BMJ Global Health</i> , 2018, 3, e000828.	4.7	10
53	Monetary and nonmonetary household consumption of health services and the role of insurance benefits: An analysis of the Mexico's National Household Income and Expenditure Survey. <i>International Journal of Health Planning and Management</i> , 2018, 33, 847-859.	1.7	8
54	Access to medicines for asthma, diabetes and hypertension in eight counties of Kenya. <i>Tropical Medicine and International Health</i> , 2018, 23, 879-885.	2.3	16

#	ARTICLE	IF	CITATIONS
55	Comparative analysis of essential medicines for cardiovascular diseases in countries of the WHO Eastern Mediterranean Region. <i>Eastern Mediterranean Health Journal</i> , 2018, 24, 427-434.	0.8	5
56	How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 307-321.	2.1	111
57	Essential medicines for universal health coverage – Authors' reply. <i>Lancet</i> , The, 2017, 389, 1881-1882.	13.7	11
58	Industry-Led Access-To-Medicines Initiatives In Low- And Middle-Income Countries: Strategies And Evidence. <i>Health Affairs</i> , 2017, 36, 706-713.	5.2	19
59	Beyond availability and affordability: how access to medicines affects non-communicable disease outcomes. <i>Lancet Public Health</i> , The, 2017, 2, e390-e391.	10.0	8
60	Health facility and skilled birth deliveries among poor women with Jamkesmas health insurance in Indonesia: a mixed-methods study. <i>BMC Health Services Research</i> , 2017, 17, 105.	2.2	28
61	Comparison of medicines management strategies in insurance schemes in middle-income countries: four case studies. <i>Journal of Pharmaceutical Policy and Practice</i> , 2017, 10, 17.	2.4	8
62	Essential medicines for universal health coverage. <i>Lancet</i> , The, 2017, 389, 403-476.	13.7	366
63	International short-term medical missions: a systematic review of recommended practices. <i>International Journal of Public Health</i> , 2017, 62, 31-42.	2.3	34
64	Study protocol for a cluster-randomised controlled trial of an NCD access to medicines initiative: evaluation of Novartis Access in Kenya. <i>BMJ Open</i> , 2016, 6, e013386.	1.9	13
65	Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries. <i>Circulation</i> , 2016, 133, 2076-2085.	1.6	122
66	Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 9.	2.4	16
67	How much could be saved in Chinese hospitals in procurement of anti-hypertensives and anti-diabetics?. <i>Journal of Medical Economics</i> , 2016, 19, 881-888.	2.1	8
68	Impact of the introduction of mandatory generic substitution in South Africa: private sector sales of generic and originator medicines for chronic diseases. <i>Tropical Medicine and International Health</i> , 2016, 21, 1504-1512.	2.3	4
69	Response by Wirtz et al to Letter Regarding Article, "Access to Medications for Cardiovascular Diseases in Low- and Middle-Income Countries". <i>Circulation</i> , 2016, 134, e305-e306.	1.6	1
70	Effects of over-the-counter sales restriction of antibiotics on substitution with medicines for symptoms relief of cold in Mexico and Brazil: time series analysis. <i>Health Policy and Planning</i> , 2016, 31, 1291-1296.	2.7	7
71	Challenges of medicines management in the public and private sector under Ghana's National Health Insurance Scheme – A qualitative study. <i>Journal of Pharmaceutical Policy and Practice</i> , 2016, 9, 6.	2.4	26
72	Estimating the Burden of Chagas Disease in the United States. <i>PLoS Neglected Tropical Diseases</i> , 2016, 10, e0005033.	3.0	174

#	ARTICLE	IF	CITATIONS
73	Seasonal Variation in Penicillin Use in Mexico and Brazil: Analysis of the Impact of Over-the-Counter Restrictions. <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 105-110.	3.2	30
74	Evaluating the Implementation of Mexico's Health Reform: The Case of <i>Seguro Popular</i> . <i>Health Systems and Reform</i> , 2015, 1, 217-228.	1.2	51
75	Reply to "Decrease in Penicillin Sales in Brazil after Over-the-Counter Restrictions". <i>Antimicrobial Agents and Chemotherapy</i> , 2015, 59, 5864-5864.	3.2	1
76	Access to Care for Chagas Disease in the United States: A Health Systems Analysis. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 108-113.	1.4	94
77	Essential medicines are still essential. <i>Lancet, The</i> , 2015, 386, 1601-1603.	13.7	29
78	Antenatal Care Among Poor Women in Mexico in the Context of Universal Health Coverage. <i>Maternal and Child Health Journal</i> , 2015, 19, 2314-2322.	1.5	9
79	Access to Medicines by Seguro Popular Beneficiaries: Pending Tasks towards Universal Health Coverage. <i>PLoS ONE</i> , 2015, 10, e0136823.	2.5	20
80	Evaluating the quality and use of economic data in decisions about essential medicines. <i>Bulletin of the World Health Organization</i> , 2015, 93, 693-699.	3.3	4
81	Obstetric Care and Method of Delivery in Mexico: Results from the 2012 National Health and Nutrition Survey. <i>PLoS ONE</i> , 2014, 9, e104166.	2.5	28
82	Effects of the expansion of doctors' offices adjacent to private pharmacies in Mexico: secondary data analysis of a national survey. <i>BMJ Open</i> , 2014, 4, e004669.	1.9	24
83	Increasing Access to Treatment for Chagas Disease: The Case of Morelos, Mexico. <i>American Journal of Tropical Medicine and Hygiene</i> , 2014, 91, 1125-1127.	1.4	4
84	A research agenda to promote affordable and quality assured medicines. <i>Journal of Pharmaceutical Policy and Practice</i> , 2014, 7, 2.	2.4	5
85	Operational rules for the implementation of INN prescribing. <i>International Journal of Medical Informatics</i> , 2014, 83, 47-56.	3.3	6
86	Analysing policy interventions to prohibit over-the-counter antibiotic sales in four Latin American countries. <i>Tropical Medicine and International Health</i> , 2013, 18, 665-673.	2.3	53
87	Promotion of access to essential medicines for non-communicable diseases: practical implications of the UN political declaration. <i>Lancet, The</i> , 2013, 381, 680-689.	13.7	190
88	Measuring universities' commitments to global health. <i>Lancet, The</i> , 2013, 382, 204-205.	13.7	1
89	Use of antibacterial fixed-dose combinations in the private sector in eight Latin American Countries between 1999 and 2009. <i>Tropical Medicine and International Health</i> , 2013, 18, 416-425.	2.3	11
90	Reforming antiretroviral price negotiations and public procurement: the Mexican experience. <i>Health Policy and Planning</i> , 2013, 28, 1-10.	2.7	13

#	ARTICLE	IF	CITATIONS
91	The Market Dynamics of Generic Medicines in the Private Sector of 19 Low and Middle Income Countries between 2001 and 2011: A Descriptive Time Series Analysis. PLoS ONE, 2013, 8, e74399.	2.5	44
92	Impact of Over-the-Counter Restrictions on Antibiotic Consumption in Brazil and Mexico. PLoS ONE, 2013, 8, e75550.	2.5	98
93	Financing HIV Programming: How Much Should Low- And Middle-Income Countries and their Donors Pay?. PLoS ONE, 2013, 8, e67565.	2.5	19
94	A new entity for the negotiation of public procurement prices for patented medicines in Mexico. Bulletin of the World Health Organization, 2012, 90, 788-792.	3.3	25
95	Oseltamivir storage, distribution and dispensing following the 2009 H1N1 influenza outbreak in Mexico. Bulletin of the World Health Organization, 2012, 90, 782-787.	3.3	9
96	Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America. Health Policy and Planning, 2012, 27, 638-648.	2.7	11
97	Indicators of quality use of medicines in South&East Asian countries: a systematic review. Tropical Medicine and International Health, 2012, 17, 1552-1566.	2.3	9
98	Heterogeneous Effects of Health Insurance on Out-of-Pocket Expenditure on Medicines in Mexico. Value in Health, 2012, 15, 593-603.	0.3	55
99	Policies to promote use of generic medicines in low and middle income countries: A review of published literature, 2000&2010. Health Policy, 2012, 106, 211-224.	3.0	99
100	Regulation of antibiotic sales in Mexico: an analysis of printed media coverage and stakeholder participation. BMC Public Health, 2012, 12, 1051.	2.9	37
101	Access to medicines among internally displaced and non-displaced people in urban areas in Colombia. Cadernos De Saude Publica, 2012, 28, 2245-2256.	1.0	5
102	Unit Costs for Delivery of Antiretroviral Treatment and Prevention of Mother-to-Child Transmission of HIV. Pharmacoeconomics, 2011, 29, 579-599.	3.3	50
103	Optimizing HIV treatment programs. Current Opinion in HIV and AIDS, 2010, 5, 232-236.	3.8	5
104	Ambulatory health service users' experience of waiting time and expenditure and factors associated with the perception of low quality of care in Mexico. BMC Health Services Research, 2010, 10, 178.	2.2	12
105	Improving access to treatment for HIV in sub-Saharan Africa. BMJ: British Medical Journal, 2010, 341, c6546-c6546.	2.3	1
106	Access to medicines by ambulatory health service users in Mexico: an analysis of the national health surveys 1994 to 2006. Salud Publica De Mexico, 2010, 52, 30-38.	0.4	4
107	Trends in antibiotic utilization in eight Latin American countries, 1997-2007. Revista Panamericana De Salud Publica/Pan American Journal of Public Health, 2010, 27, 219-25.	1.1	99
108	Strategies and ethical considerations for the recruitment of young men who have sex with men: challenges of a vaccination trial in Mexico. Clinical Trials, 2009, 6, 365-372.	1.6	4

#	ARTICLE	IF	CITATIONS
109	Factors influencing global antiretroviral procurement prices. BMC Public Health, 2009, 9, S6.	2.9	22
110	Pharmacy customers' knowledge of side effects of purchased medicines in Mexico. Tropical Medicine and International Health, 2009, 14, 93-100.	2.3	12
111	Organizational elements of health service related to a reduction in maternal mortality: The cases of Chile and Colombia. Health Policy, 2009, 90, 149-155.	3.0	14
112	Medicines in Mexico, 1990-2004: systematic review of research on access and use. Salud Publica De Mexico, 2008, 50, S470-S479.	0.4	17